

Financial Tear Sheet

Corporate Profile

We are a clinical stage biopharmaceutical company developing novel therapies for the management of pain and other central nervous system, or CNS, disorders. By focusing on this therapeutic area, we are addressing significant and growing markets where current treatment options are limited or inadequate. Our product candidate portfolio includes two late-stage candidates, AXS-02 and AXS-05, which we are developing for multiple indications.

We aim to become a fully integrated biopharmaceutical company that develops and commercializes differentiated therapies that expand the treatment options available to caregivers and improve the lives of patients living with pain and other CNS disorders.

Stock Information

AXSM (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$2.36
Change (%)	▼ 0.04 (1.67%)
Volume	4,952
52 Week High	\$6.45
52 Week Low	\$2.05
Market Cap	\$63,006,869
Rolling EPS	-1.09
PE Ratio	0
Shares Outstanding	26,252,862



Data as of August 15, 2018 9:42 a.m. ET

Recent Headlines

August 8, 2018

Axsome Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update

August 1, 2018

Axsome Therapeutics to Report Second Quarter 2018 Financial Results on August 8, 2018

July 17, 2018

Axsome Therapeutics Announces AXS-05 Presentation at the 2018 Alzheimer's Association International Conference

SEC Filings

Filing Date	Form
August 13, 2018	S-8
August 8, 2018	10-Q
August 8, 2018	8-K
August 8, 2018	8-K

Upcoming Events

There are currently no events scheduled.